WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406445
CAS#: 1052532-15-6
Description: SBE-13 is a selective inhibitor of PLK1 (IC50 values are 200 pM, 875 nM and 66 μ M for PLK1, PLK3 and PLK2 respectively).
MedKoo Cat#: 406445
Name: SBE-13 HCl
CAS#: 1052532-15-6
Chemical Formula: C24H27ClN2O4
Exact Mass: 442.16594
Molecular Weight: 442.93518
Elemental Analysis: C, 65.08; H, 6.14; Cl, 8.00; N, 6.32; O, 14.45
SBE-13 HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: SBE13; SBE 13; SBE13; SBE-13 HCl.
IUPAC/Chemical Name: N-(4-((6-chloropyridin-3-yl)methoxy)-3-methoxybenzyl)-2-(3,4-dimethoxyphenyl)ethanamine hydrochloride
InChi Key: QBGSVDJLQQXEGG-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H27ClN2O4.ClH/c1-28-20-7-4-17(12-22(20)29-2)10-11-26-14-18-5-8-21(23(13-18)30-3)31-16-19-6-9-24(25)27-15-19;/h4-9,12-13,15,26H,10-11,14,16H2,1-3H3;1H
SMILES Code: COC1=CC=C(CCNCC2=CC=C(OCC3=CC=C(Cl)N=C3)C(OC)=C2)C=C1OC.[H]Cl
The following data is based on the product molecular weight 442.93518 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Eckerdt F. Polo-like kinase 1 inhibitors SBE13 and BI 2536 induce different responses in primary cells. Cell Cycle. 2011 Apr 1;10(7):1027-8. Epub 2011 Apr 1. PubMed PMID: 21415595.
2: Posern G. Should I stall or should I cycle? An inhibitor for Polo-like Kinase 1 with distinct roles in primary cells. Cell Cycle. 2011 Apr 1;10(7):1029-30. Epub 2011 Apr 1. PubMed PMID: 21412046.
3: Keppner S, Proschak E, Schneider G, Spänkuch B. Fate of primary cells at the G1/S boundary after polo-like kinase 1 inhibition by SBE13. Cell Cycle. 2011 Feb 15;10(4):708-20. Epub 2011 Feb 15. PubMed PMID: 21301227.
4: Eckerdt F. Freezing Polo in its sleep: targeting the inactive conformation of Polo-like kinase 1 in cancer cells. Cell Cycle. 2010 Mar 1;9(5):862. Epub 2010 Mar 1. PubMed PMID: 20348843.
5: Keppner S, Proschak E, Kaufmann M, Strebhardt K, Schneider G, Spänkuch B. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle. 2010 Feb 15;9(4):761-73. Epub 2010 Feb 16. PubMed PMID: 20139717.
6: Liu X. SBE13 joins the family of Polo-like kinase 1 (Plk1) inhibitors. Cell Cycle. 2010 Feb 1;9(3):445-6. Epub 2010 Feb 1. PubMed PMID: 20130451.
7: Keppner S, Proschak E, Schneider G, Spänkuch B. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. ChemMedChem. 2009 Nov;4(11):1806-9. doi: 10.1002/cmdc.200900338. PubMed PMID: 19746360.